November, 2024

Oral Presentation: A phase 1 dose-escalation and expansion study of CUE-101 as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer

November, 2024

Poster Presentation: A phase 1 trial of CUE-102, a novel WT1-pHLA-IL2-Fc T cell engager in HLA-A*0201 positive patients with WT1-positive recurrent/metastatic cancers

June, 2024

Oral Presentation: A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck squamous cell cancer (R/M HNSCC). Presented by, Douglas R. Adkins, M.D., Professor of Medicine, Washington University School of Medicine, St. Louis, and a principal investigator participating in the CUE-101 clinical trial

June, 2024

Poster Presentation: A phase 1 dose escalation and expansion study of CUE-102, a novel WT1-pHLA-IL2-Fc fusion protein, in HLA-A*0201- positive patients with WT1-positive recurrent/metastatic cancers

November, 2023

Poster Presentation: A phase 1 trial of CUE-102, a novel WT1-pHLA-IL2-Fc fusion protein in HLA-A*0201 positive patients with WT1-positive recurrent/metastatic cancers

November, 2023

Poster Presentation: A phase 1 dose-escalation and expansion study of CUE-101, given as monotherapy in 3L and in combination with pembrolizumab in 1L recurrent/metastatic HPV16+ head and neck cancer patients

June, 2023

Poster Presentation: A phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer.

November, 2022

Poster Presentation: A phase 1 study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer

November, 2022

Poster Presentation: A phase 1, open-label, dose escalation and expansion study of CUE-102 monotherapy in HLA-A*0201 positive patients with WT1-positive recurrent/metastatic cancers

November, 2022

Poster Presentation: CUE-102 selectively activates and expands WT1-specific T cells for the treatment of patients with WT1+ malignancies

June, 2022

Poster Presentation: A Phase 1 dose-escalation and expansion study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, given alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer

May, 2022

Poster Presentation: CUE-102 Selectively Activates and Expands WT1-Specific T Cells for the Treatment of Patients with WT1+ Malignancies

February, 2022

Poster Presentation: Integration of IL-2 signaling at the immunological synapse

Collaboration with the laboratory of Michael Dustin at the University of Oxford

November, 2021

Poster Presentation: A phase 1 trial of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer

November, 2021

Poster Presentation: CUE-102 selectively activates and expands WT1-specific T cells for the treatment of patients with WT1+ malignancies

October, 2021

The Journal of Clinical Investigation; October 21, 2021 DOI: 10.1172/JCI141051

Mengyan Li, Scott J. Garforth, Kaitlyn E. O’Connor, Hang Su, Danica Lee, Alev Celikgil, Rodolfo J. Chaparro, Ronald Seidel, R. Brad Jones, Ravit Arav-Boger, Steven C. Almo and Harris Goldstein

September, 2021

Nature Portfolio, Scientific Reports; September 28, 2021 DOI: 10.1038/s41598-021-98716-z

Ronald D. Seidel, Zohra Merazga, Dharma Raj Thapa, Jonathan Soriano, Emily Spaulding, Ahmet S. Vakkasoglu, Paige Ruthardt, Wynona Bautista, Steven N. Quayle, Peter A. Kiener, Simon Low, John F. Ross, Saso Cemerski, Anish Suri, Steven C. Almo & Rodolfo J. Chaparro

June, 2021

Video: CUE-401: A novel IL-2/TGF-beta fusion protein for the induction of CD4+ FOXP3+ regulatory T cells

Download Poster

May, 2021

Poster Presentation: Immuno-STAT™ (Selective Targeting and Alteration of T cells) Platform: Targeting Tumor Heterogeneity and Tumor Escape Mechanisms

January, 2021

Presentation: Directly Targeting Autoantigen-Specific T cells with Immuno-STATs

September, 2020

Nature Methods 2020; September 14, 2020 DOI: 10.1038/s41592-020-0934-5

Andrew W. Woodham, Stad H. Zeigler, Ella L. Zeyang, Stephen C. Kolifrath, Ross W. Cheloha, Mohammad Rashidian, Rodolfo J. Chaparro, Ronald D. Seidel, Scott J. Garforth, Jason L. Dearling, Maia Mesyngier, Phaneendra K. Duddempudi, Alan B. Packard, Steven C. Almo & Hidde L. Ploegh

August, 2020

Video Poster Presentation: Neo-STAT™: A new biologics platform for selective targeting of tumor-specific T cells with enhanced antigen modularity

June, 2020

PLOS One 2020; June 4, 2020 DOI: 10.1371/Journal PONE.0233578

Sarah C. Garrett-Thomson, Aldo Massimi, Elena V. Fedorov, Jeffrey B. Bonanno, Lisa Scandiuzzi, Brandan Hillerich, Ronald D. Seidel, III, James D. Love, Scott J. Garforth, Chandan Guha, Steven C. Almo

January, 2020

Clinical Cancer Research 2020; January 21, 2020 DOI: 10.1158/1078-0432.CCR-19-3354

Steven N Quayle, Natasha Girgis, Dharma R Thapa, Zohra Merazga, MelissaM Kemp, Alex Histed, Fan Zhao, Miguel Moreta, Paige Ruthardt, Sandrine Hulot, Alyssa Nelson, Lauren D Kraemer, Dominic R Beal, Luke Witt, Jessica Ryabin, Jonathan Soriano, Mark Haydock, Emily Spaulding, John F Ross, PeterA Kiener, Steven Almo, Rodolfo Chaparro, Ronald Seidel, Anish Suri, Saso Cemerski, Kenneth J. Pienta and Mary Ellen Simcox

November, 2019

Poster Presentation: CUE-101, a Novel HPV16 E7:pMHC:IL-2:Fc Fusion Protein, Enhances Tumor Antigen Specific T Cell Activation for the Treatment of HPV16-Driven Malignancies

April, 2019

Video: Diagnostic & disease detection to transform biopharma

January, 2019

Poster Presentation: CUE-101, a novel Fc fusion protein for selective targeting and expansion of anti-tumor T cells for treatment of HPV-driven malignancies